Skip to main content

This job has expired

You will need to login before you can apply for a job.

Principal Scientist, Cell Therapy Process Development

Employer
Intellia Therapeutics
Location
Cambridge, MA, United States
Start date
Jul 2, 2021

View more

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We want all of our people to go beyond what is possible. We aren't constrained by typical end rails, and we aren't out to just treat people. We're all in this for something more. We're driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

Title: Principal Scientist, Cell Therapy Process Development

How you will Achieve More with Intellia:

We are excited to welcome this new member to our growing Technical Operations team and company. This role is both hands-on and strategic. We are looking for a candidate that has direct experience with process development for T cell manufacture. If you thrive in a highly collaborative environment with good communication and troubleshooting skills, this role may be for you!

As (Sr.) Principal Scientist in Cell Therapy Process Development, you will work on various projects including:

  • Leading development and optimization activities to establish platform T cell therapies, considering Quality by Design and closed systems.
  • Evaluating and identifying key performance parameters for T cell processes using CRISPR gene editing tools and both non-viral and viral template delivery within a cross-functional team.
  • Aiding in technology transfer of T cell process to CDMO, including review of protocols, MBRs, and reports, aligning with quality assurance expectations.
  • Coordinating characterization of T cells during process development activities in partnership with analytical development
  • Participating in strategic program discussions and providing high quality data driven decision making within the CMC team
  • Overseeing and training junior process development team members, including experimental design oversight.


We are looking for a candidate that has a PhD in Biochemistry, Biology, Biological Engineering, or Immunology with 5+ years hands-on experience, or master's degree with 11+ years. Preference will be given to candidates with experience in aseptic cell culture, closed systems process, and cryo-banking.

Meet your future team:

The Cell Therapy Process development team is a motivated team driven to deliver robust manufacturing processes for patient treatment. You will report to the Associate Director, Cell Therapy Process Development. This team is responsible for developing, scaling, and tech transferring each process unit of T cell production, including cell selection, media optimization, gene editing, expansion, harvest, and cryopreservation.

We are looking to expand our team of 7 dedicated individuals that work closely to meet program milestones. Through a combination of lab-based and remote activities, the team balances hands on experiments at our Cambridge, MA based facility with virtual cross-functional interactions. You can expect to join a hardworking group, a collaborative environment, and a community that values virtual happy hours and game nights.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert